Insulet International is the European operational arm of Insulet Corporation, a leader in tubeless insulin pump technology with its Omnipod® Insulin Management System. Since July 1, 2018, Insulet International has transitioned to direct operations in Europe, establishing a dedicated commercial team deeply knowledgeable about diabetes care and local market dynamics. This move marked a significant strategic shift allowing the company to manage sales, marketing, training, and customer support directly rather than through third parties, facilitating closer connections with European customers and healthcare professionals. To support this expansion, Insulet partnered with established companies in Europe for customer care, product support, and logistics services, ensuring seamless delivery and service continuity across the continent. Their approach emphasizes long-term support and adaptation to customer needs in Europe, aligning with their operations in the US and Canada.
Insulet International operates within the framework of the EU Transparency Register, which mandates disclosure of entities influencing EU policy and decision-making for accountability and transparency. While specific details about their lobbying activities, including lobbyists employed or affiliated networks, are not publicly detailed in the register extracts, Insulet’s presence in the register confirms its engagement in EU policy dialogue concerning diabetic care technologies and healthcare regulations. As a provider of critical medical technology, their lobbying activities likely focus on regulatory frameworks for medical devices, reimbursement policies, and diabetes patient care standards within the EU.
This international expansion by Insulet underscores a broader trend of healthcare technology companies optimizing their regulatory and commercial presence in key markets across Europe, directly engaging with stakeholders and policymakers to ensure supportive environments for innovative health solutions. Their commitment to transparency, customer support excellence, and regulatory compliance positions them as a proactive participant in the EU healthcare market.
